# EDGAR Filing Document

**Accession Number:** 0001640266
**File Stem:** 0001104659-25-057820
**Filing Date:** 2025-6
**Character Count:** 31887
**Document Hash:** 927ac863e9b00cfb49bc1a4617ccebdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-057820.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001104659-25-057820

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**EFFECTIVENESS DATE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Voyager Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001640266
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287879
- **FILM NUMBER:** 251034108

**BUSINESS ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 857-259-5340

**MAIL ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**As filed with the Securities and Exchange Commission on June 9, 2025**

Registration No. 333-

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER<br> THE SECURITIES ACT OF 1933**

**VOYAGER THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**46-3003182** |
| &nbsp;&nbsp;(State or Other Jurisdiction of Incorporation or <br> Organization) | &nbsp;&nbsp;(I.R.S. Employer Identification No.) |
| &nbsp;&nbsp;**75 Hayden Avenue, Lexington, MA** | &nbsp;&nbsp;**02421** |
| &nbsp;&nbsp;(Address of Principal Executive Offices) | &nbsp;&nbsp;(Zip Code) |

---

**2025 Stock Incentive Plan**

(Full Title of the Plan)

**Alfred Sandrock**

**President and Chief Executive Officer**

**Voyager Therapeutics, Inc.**

**75 Hayden Avenue**

**Lexington, Massachusetts 02421**<br> (Name and Address of Agent for Service)

**(857) 259-5340**

(Telephone Number, Including Area Code, of Agent for Service)

Copies to:

---

| | |
|:---|:---|
| **Brian A. Johnson, Esq. <br> C. S. Avery Reaves, Esq. <br> Wilmer Cutler Pickering Hale and Dorr LLP <br> 7 World Trade Center <br> 250 Greenwich Street <br> New York, New York 10007 <br> (212) 230-8800** | **Jacquelyn Fahey Sandell, Esq.<br> Chief Legal Officer<br> Voyager Therapeutics, Inc.<br> 75 Hayden Avenue<br> Lexington, Massachusetts 02421<br> (857) 259-5340** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ⌧ <br> Non-accelerated filer ◻ Smaller reporting company ◻ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**PART I** **<br> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1.** **Plan Information.**

The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act") and the Note to Part I of Form S-8.

**Item 2.** **Registrant Information and Employee Plan Annual Information.**

The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.

**PART II** **<br> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the registrant's [Annual Report on Form 10-K for the fiscal year ended December 31, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025002703/vygr-20241231x10k.htm), as filed with the Commission on March 11, 2025, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our [definitive proxy statement](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm) for the 2025 Annual Meeting of Stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [the registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, as filed with the Commission on May 6, 2025;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025006484/vygr-20250331x10q.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the registrant's Current Reports on Form 8-K as filed with the Commission on [February 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000110465925011155/tm256087d1_8k.htm) and [June 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000110465925056835/tm2517216d2_8k.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The description of the securities contained in our Registration Statement on [Form 8-A (File No. 001-37625) as filed with the Commission on November 6, 2015](https://www.sec.gov/Archives/edgar/data/1640266/000110465915076735/a15-22556_18a12b.htm), as the description therein has been updated and superseded by the description of the registrant's securities contained in [Exhibit 4.4](https://www.sec.gov/Archives/edgar/data/1640266/000155837020001974/ex-4d4.htm) to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Commission on March 3, 2020, and including any amendments and reports filed for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 4.** **Description of Securities.**

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.**

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.**

The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law ("DGCL") and the Fifth Amended and Restated Certificate of Incorporation ("Certificate") and the Amended and Restated Bylaws of the registrant ("Bylaws").

Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

Section 102(b)(7) of the DGCL provides, generally, that a corporation's certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of a director or officer (i) for any breach of the director's or officer's duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for a director, under Section 174 of the DGCL, (iv) for any transaction from which the director or officer derived an improper personal benefit or (v) for an officer, in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.

The Certificate and Bylaws limit or eliminate the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL and provide that no director will have personal liability to the registrant or to its stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of directors:

&nbsp;&nbsp;&nbsp;&nbsp;· for any breach of the director's duty of loyalty to the registrant or its stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;· for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

&nbsp;&nbsp;&nbsp;&nbsp;· for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or

&nbsp;&nbsp;&nbsp;&nbsp;· for any transaction from which the director derived an improper personal benefit.

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, the Bylaws provide that the corporation:

&nbsp;&nbsp;&nbsp;&nbsp;· will indemnify its directors, officers and, in the discretion of the board of directors, certain employees to the fullest extent permitted
by the DGCL, as the DGCL now exists or may in the future be amended; and

&nbsp;&nbsp;&nbsp;&nbsp;· will advance reasonable expenses, including attorneys' fees, to its directors and, in the discretion of the board of directors,
to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the registrant,
subject to limited exceptions.

The registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the registrant will indemnify the director or executive officer to the fullest extent permitted by Delaware law for claims arising in his or her capacity as a director or officer of the registrant or in connection with their service at the registrant's request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer. Such agreements include the advancement of expenses, including attorneys' fees (but excluding judgments, fines and settlement amounts).

Additionally, certain of the directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates, which indemnification relates to and might apply to the same proceedings arising out of such director's services as a director referenced herein. Nonetheless, the registrant has agreed in the indemnification agreements that the registrant's obligations to those same directors are primary and any obligation of the affiliates of those directors to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary. The registrant also maintains a general liability insurance policy which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

**Item 7.** **Exemption from Registration Claimed.**

Not applicable.

**Item 8.** **Exhibits.**

The following exhibits are incorporated herein by reference:

---

| | |
|:---|:---|
| <u>Number</u> | <u>Description</u> |
| [4.1](https://www.sec.gov/Archives/edgar/data/1640266/000155837018002038/vygr-20171231ex4167a89f3.htm) | [Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant's Annual Report on Form 10-K (File No. 001-37625) filed on March 14, 2018).](https://www.sec.gov/Archives/edgar/data/1640266/000155837018002038/vygr-20171231ex4167a89f3.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1640266/000110465915079337/a15-23518_1ex3d1.htm) | [Fifth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37625) filed on November 16, 2015).](https://www.sec.gov/Archives/edgar/data/1640266/000110465915079337/a15-23518_1ex3d1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1640266/000110465915079337/a15-23518_1ex3d2.htm) | [Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-37625) filed on November 16, 2015).](https://www.sec.gov/Archives/edgar/data/1640266/000110465915079337/a15-23518_1ex3d2.htm) |
| [5.1\*](tm2517216d1_ex5-1.htm) | [Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant](tm2517216d1_ex5-1.htm) |
| [23.1\*](tm2517216d1_ex5-1.htm) | [Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)](tm2517216d1_ex5-1.htm) |
| [23.2\*](tm2517216d1_ex23-2.htm) | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm](tm2517216d1_ex23-2.htm) |
| [24\*](#a_001) | [Power of attorney (included on the signature pages of this registration statement)](#a_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixA) | [Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (Incorporated by reference to Appendix A of the Registrant's Definitive Proxy Statement on Schedule 14A (File No. 001-37625) filed on April 23, 2025).](https://www.sec.gov/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixA) |
| [107\*](tm2517216d1_ex-filingfees.htm) | [Filing Fee Table](tm2517216d1_ex-filingfees.htm) |

---

\* Filed herewith

**Item 9.** **Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Lexington, Massachusetts, on this 9<sup>th</sup> day of June, 2025.

---

| | |
|:---|:---|
| VOYAGER THERAPEUTICS, INC. | VOYAGER THERAPEUTICS, INC. |
| By: | /s/ Alfred Sandrock, M.D., Ph.D. |
|  | Alfred Sandrock, M.D., Ph.D. |
|  | Chief Executive Officer and President |

---

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Voyager Therapeutics, Inc., hereby severally constitute and appoint Alfred Sandrock and Nathan Jorgensen, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Voyager Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Alfred Sandrock, M.D., Ph.D.* | Chief Executive Officer, President, and Director | June 9, 2025 |
| Alfred Sandrock, M.D., Ph.D. | *(Principal Executive Officer)* |  |
| */s/ Nathan Jorgensen, Ph.D., MBA* | Chief Financial Officer | June 9, 2025 |
| Nathan Jorgensen, Ph.D., MBA | *(Principal Financial and Accounting Officer)* |  |
| */s/ Michael Higgins* | Director (Chairman of the Board) | June 9, 2025 |
| Michael Higgins |  |  |
| */s/ Grace E. Colón, Ph.D.* | Director | June 9, 2025 |
| Grace E. Colón, Ph.D. |  |  |
| */s/ James Geraghty* | Director | June 9, 2025 |
| James Geraghty |  |  |
| */s/ Steven Hyman, M.D.* | Director | June 9, 2025 |
| Steven Hyman, M.D. |  |  |
| */s/ Catherine J. Mackey, Ph.D.* | Director | June 9, 2025 |
| Catherine J. Mackey, Ph.D. |  |  |
| */s/ Jude Onyia, Ph.D.* | Director | June 9, 2025 |
| Jude Onyia, Ph.D. |  |  |
| */s/ Glenn Pierce, M.D., Ph.D.* | Director | June 9, 2025 |
| Glenn Pierce, M.D., Ph.D. |  |  |
| */s/ George Scangos, Ph.D.* | Director | June 9, 2025 |
| George Scangos, Ph.D. |  |  |
| */s/ Nancy Vitale* | Director | June 9, 2025 |
| Nancy Vitale |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm2517216d1_ex5-1img001.jpg)

June 9, 2025 <br> Voyager Therapeutics, Inc. 75 Hayden Avenue Lexington, Massachusetts 02421 +1 617 526 6000 (t) +1 617 526 5000 (f) wilmerhale.com

Re: 2025 Stock Incentive Plan

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 17,822,928 shares of common stock, $0.001 par value per share (the "Shares"), of Voyager Therapeutics, Inc., a Delaware corporation (the "Company"), issuable under the Company's 2025 Stock Incentive Plan (the "Plan").

We have examined the Certificate of Incorporation and Bylaws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plan and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plan, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

![](tm2517216d1_ex5-1img002.jpg)

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plan, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Wilmer Cutler Pickering Hale and Dorr LLP |
| WILMER CUTLER PICKERING HALE AND DORR LLP |

---

## Exhibit 23.2

**Exhibit 23.2**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. of our reports dated March 11, 2025, with respect to the consolidated financial statements of Voyager Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Voyager Therapeutics, Inc. as of December 31, 2024 included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

June 9, 2025

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

---

| |
|:---|
| &nbsp;&nbsp;**Form S-8** |
| &nbsp;&nbsp;(Form Type) |
| &nbsp;&nbsp;**Voyager Therapeutics, Inc.** |
| &nbsp;&nbsp;(Exact Name of Registrant as Specified in its Charter) |

---

**Table 1—Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Security <br> Type** | &nbsp;&nbsp;**Security<br> Class Title** | &nbsp;&nbsp;**Fee <br> Calculation<br> Rule** | &nbsp;&nbsp;**Amount<br> Registered <br> (1)** | &nbsp;&nbsp;**Proposed<br> Maximum<br> Offering<br> Price Per <br> Unit** | &nbsp;&nbsp;**Maximum <br> Aggregate <br> Offering<br> Price** | &nbsp;&nbsp;**Fee Rate** | &nbsp;&nbsp;**Amount of<br> Registration<br> Fee** |
| &nbsp;&nbsp;Equity | &nbsp;&nbsp; Common Stock, $0.001 par value per share<br>| &nbsp;&nbsp; Other<br>| &nbsp;&nbsp; 17822928 (2)<br>| &nbsp;&nbsp;$3.33 (3) | &nbsp;&nbsp;$59350351 (3) | &nbsp;&nbsp;$153.10 per $1,000,000 | &nbsp;&nbsp;$9086.54 |
| &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** |  | &nbsp;&nbsp;$59350351 |  | &nbsp;&nbsp;$9086.54 |
| &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** |  |  |  | &nbsp;&nbsp;— |
| &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** |  |  |  | &nbsp;&nbsp;$9086.54 |

---

(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2) Consists of a number of shares issuable under the 2025 Stock Incentive Plan (the "2025 Plan") equal to the sum of: (i) 3,631,952 shares of common stock; and (ii) such additional number of shares of common stock (up to 14,190,976 shares) as is equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2015 Stock Option and Incentive Plan (the "2015 Plan") that remained available for grant under the 2015 Plan immediately prior to the date that the 2025 Plan was approved by the registrant's stockholders and (y) the number of shares of common stock subject to awards granted under the 2015 Plan that were outstanding as of the date that the 2025 Plan was approved by the registrant's stockholders and which awards expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the registrant at their original issuance price pursuant to a contractual repurchase right.

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2025.